儿童脓毒症住院后新发与进展性内科疾病
脓毒症幸存者中13.0%出现新发目标疾病,21.0%原有目标疾病进展,19.4%至少出现一种疾病的新发和/或进展。脓毒症组新发慢性呼吸衰竭、补充营养依赖和慢性肾脏病风险更高,新发癫痫风险更低。
要点
- 脓毒症幸存者中约1/5在出院后6个月内出现至少一种目标疾病的新发和/或进展。
- 脓毒症组新发慢性呼吸衰竭、补充营养依赖和慢性肾脏病风险高于非脓毒症危重住院组。
- 脓毒症组新发癫痫风险低于非脓毒症危重住院组,进展性癫痫风险亦较低。
核心结论
- 在危重儿童脓毒症幸存者中,约五分之一在出院后6个月内出现目标疾病的新发或进展。
- 脓毒症幸存者可能受益于结构化随访以识别和治疗新发或加重的内科合并症。
研究设计与样本
- 暴露为脓毒症重症监护室住院与非脓毒症全因重症监护室住院的比较。
- 主要结局为出院后6个月内4种目标疾病(慢性呼吸衰竭、癫痫、补充营养依赖、慢性肾脏病)的新发;次要结局为原有目标疾病的进展。
- 采用匹配权重的逻辑回归评估脓毒症与非脓毒症幸存者间结局差异。
主要发现
- 脓毒症队列中位年龄9.5岁(IQR 3-15岁),非脓毒症队列中位年龄7岁(IQR 2-13岁)。
- 5150例脓毒症幸存者中670例(13.0%)出现新发目标疾病,1834例原有目标疾病者中385例(21.0%)出现疾病进展。
- 5150例幸存者中998例(19.4%)出现至少一种疾病的新发和/或进展。
- 新发疾病比较:慢性呼吸衰竭4.6% vs 1.9%(OR 2.54,95%CI 2.19-2.94);补充营养依赖7.9% vs 2.7%(OR 3.17,95%CI 2.80-3.59);慢性肾脏病1.1% vs 0.6%(OR 1.65,95%CI 1.25-2.19);癫痫4.6% vs 6.0%(OR 0.77,95%CI 0.66-0.89)。
关键数值与推荐
- 目标疾病通过诊断与操作编码、耐用医疗设备编码和处方药物识别。
- 新发慢性呼吸衰竭在脓毒症组为4.6%,非脓毒症组为1.9%(OR 2.54,95%CI 2.19-2.94)。
- 新发补充营养依赖在脓毒症组为7.9%,非脓毒症组为2.7%(OR 3.17,95%CI 2.80-3.59)。
- 新发慢性肾脏病在脓毒症组为1.1%,非脓毒症组为0.6%(OR 1.65,95%CI 1.25-2.19)。
- 新发癫痫在脓毒症组为4.6%,非脓毒症组为6.0%(OR 0.77,95%CI 0.66-0.89)。
临床怎么用
- 儿科脓毒症幸存者出院后应关注慢性呼吸衰竭、补充营养依赖和慢性肾脏病的新发风险。
- 对脓毒症幸存者考虑结构化随访以识别和治疗新发或加重的内科合并症。
- 对原有目标疾病的脓毒症幸存者需监测补充营养依赖的进展。
局限性
- 研究使用行政索赔数据库,结局依赖诊断、操作、设备编码和处方药物识别。
- 研究为观察性队列设计,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Children commonly experience physical, cognitive, or emotional sequelae after sepsis. However, little is known about the development or progression of medical conditions after pediatric sepsis. OBJECTIVE: To quantify the development and progression of 4 common conditions in the 6 months after sepsis and to assess whether they differed after hospitalization for sepsis vs nonsepsis among critically ill children. DESIGN, SETTING, AND PARTICIPANTS: This cohort study of 101 511 children (<19 years) with sepsis or nonsepsis hospitalization used a national administrative claims database (January 1, 2010, to June 30, 2018). Data management and analysis were conducted from April 1, 2020, to July 7, 2022. EXPOSURES: Intensive care unit hospitalization for sepsis vs all-cause intensive care unit hospitalizations, excluding sepsis. MAIN OUTCOMES AND MEASURES: Primary outcomes were the development of 4 target conditions (chronic respiratory failure, seizure disorder, supplemental nutritional dependence, and chronic kidney disease) within 6 months of hospital discharge. Secondary outcomes were the progression of the 4 target conditions among children with the condition before hospitalization. Outcomes were identified via diagnostic and procedural codes, durable medical equipment codes, and prescription medications. Differences in the development and the progression of conditions between pediatric patients with sepsis and pediatric patients with nonsepsis who survived intensive care unit hospitalization were assessed using logistic regression with matching weights. RESULTS: A total of 5150 survivors of pediatric sepsis and 96 361 survivors of nonsepsis intensive care unit hospitalizations were identified; 2593 (50.3%) were female. The median age was 9.5 years (IQR, 3-15 years) in the sepsis cohort and 7 years (IQR, 2-13 years) in the nonsepsis cohort. Of the 5150 sepsis survivors, 670 (13.0%) developed a new target condition, and 385 of 1834 (21.0%) with a preexisting target condition had disease progression. A total of 998 of the 5150 survivors (19.4%) had development and/or progression of at least 1 condition. New conditions were more common among sepsis vs nonsepsis hospitalizations (new chronic respiratory failure: 4.6% vs 1.9%; odds ratio [OR], 2.54 [95% CI, 2.19-2.94]; new supplemental nutritional dependence: 7.9% vs 2.7%; OR, 3.17 [95% CI, 2.80-3.59]; and new chronic kidney disease: 1.1% vs 0.6%; OR, 1.65 [95% CI, 1.25-2.19]). New seizure disorder was less common (4.6% vs 6.0%; OR, 0.77 [95% CI, 0.66-0.89]). Progressive supplemental nutritional dependence was more common (1.5% vs 0.5%; OR, 2.95 [95% CI, 1.60-5.42]), progressive epilepsy was less common (33.7% vs 40.6%; OR, 0.74 [95% CI, 0.65-0.86]), and progressive respiratory failure (4.4% vs 3.3%; OR, 1.35 [95% CI, 0.89-2.04]) and progressive chronic kidney disease (7.9% vs 9.2%; OR, 0.84 [95% CI, 0.18-3.91]) were similar among survivors of sepsis vs nonsepsis admitted to an intensive care unit. CONCLUSIONS AND RELEVANCE: In this national cohort of critically ill children who survived sepsis, 1 in 5 developed or had progression of a condition of interest after sepsis hospitalization, suggesting survivors of pediatric sepsis may benefit from structured follow-up to identify and treat new or worsening medical comorbid conditions.
引用
- Carlton EF, Gebremariam A, Maddux AB, et al. New and Progressive Medical Conditions After Pediatric Sepsis Hospitalization Requiring Critical Care. JAMA Pediatr. 2022. PMID: 36215045. doi:10.1001/jamapediatrics.2022.3554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。